Your browser is no longer supported. Please, upgrade your browser.
FPRX Five Prime Therapeutics, Inc. daily Stock Chart
FPRX [NASD]
Five Prime Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.48 Insider Own1.00% Shs Outstand35.26M Perf Week0.00%
Market Cap189.53M Forward P/E- EPS next Y-2.21 Insider Trans241.51% Shs Float35.29M Perf Month61.09%
Income-121.90M PEG- EPS next Q-0.69 Inst Own69.80% Short Float3.73% Perf Quarter38.38%
Sales17.90M P/S10.59 EPS this Y5.10% Inst Trans-3.69% Short Ratio3.74 Perf Half Y40.58%
Book/sh3.82 P/B1.39 EPS next Y12.10% ROA-49.80% Target Price8.00 Perf Year-37.35%
Cash/sh3.95 P/C1.34 EPS next 5Y- ROE-72.80% 52W Range1.75 - 8.81 Perf YTD15.47%
Dividend- P/FCF- EPS past 5Y-16.90% ROI-94.30% 52W High-39.84% Beta2.81
Dividend %- Quick Ratio7.80 Sales past 5Y-5.00% Gross Margin- 52W Low202.86% ATR0.47
Employees87 Current Ratio7.80 Sales Q/Q58.50% Oper. Margin- RSI (14)65.57 Volatility12.10% 11.63%
OptionableYes Debt/Eq0.00 EPS Q/Q43.90% Profit Margin- Rel Volume1.06 Prev Close5.01
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume352.18K Price5.30
Recom2.50 SMA2023.17% SMA5061.85% SMA20025.87% Volume374,220 Change5.79%
Feb-28-20Downgrade JP Morgan Neutral → Underweight
Feb-18-20Downgrade Wedbush Outperform → Neutral
Nov-20-19Resumed Guggenheim Neutral
Oct-01-19Downgrade Guggenheim Buy → Neutral
Jun-03-19Downgrade Wells Fargo Outperform → Market Perform
May-29-19Initiated ROTH Capital Neutral $10
Apr-12-19Resumed Guggenheim Buy $24
Sep-13-18Resumed Leerink Partners Outperform $24
Jun-28-18Initiated Raymond James Mkt Perform
Jun-15-18Initiated JP Morgan Neutral $19
May-18-18Initiated Wedbush Neutral
Nov-06-17Reiterated RBC Capital Mkts Outperform $41 → $50
Sep-15-17Initiated RBC Capital Mkts Outperform $41
Mar-02-17Initiated Instinet Buy $94
Oct-25-16Initiated Citigroup Buy
Jan-21-16Initiated Credit Suisse Outperform
Dec-04-15Resumed Wells Fargo Outperform
Oct-19-15Reiterated Oppenheimer Outperform $45 → $48
Jul-31-15Initiated Citigroup Buy
May-15-15Initiated Oppenheimer Outperform $45
May-29-20 12:38PM  Edited Transcript of FPRX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents +5.79%
May-15-20 09:37AM  Is Five Prime Therapeutics (FPRX) Stock a Solid Choice Right Now? Zacks
May-10-20 09:55AM  Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
May-07-20 04:05PM  Five Prime Therapeutics Reports First Quarter 2020 Results Business Wire +11.14%
Apr-30-20 04:05PM  Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call Business Wire
Apr-22-20 04:05PM  Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format Business Wire
Apr-14-20 09:00AM  Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer Business Wire +7.35%
Apr-09-20 07:35AM  Here's Why Five Prime Therapeutics (NASDAQ:FPRX) Must Use Its Cash Wisely Simply Wall St. +10.20%
Mar-20-20 03:32AM  Edited Transcript of FPRX earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-13-20 09:25AM  Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology Business Wire
Feb-27-20 05:45PM  Five Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue Estimates Zacks -10.56%
Feb-25-20 04:22PM  Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire -7.24%
Feb-20-20 12:31PM  Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-19-20 09:25AM  Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs Business Wire +18.33%
Feb-18-20 09:25AM  Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer Business Wire
Feb-13-20 04:05PM  Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call Business Wire -8.11%
Jan-10-20 09:28AM  If You Had Bought Five Prime Therapeutics (NASDAQ:FPRX) Stock Three Years Ago, You'd Be Sitting On A 89% Loss, Today Simply Wall St. -6.00%
Dec-30-19 01:05PM  Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-19 02:26PM  Longtime biotech exec walks away from board to concentrate on startup American City Business Journals
Dec-26-19 04:05PM  Five Prime Therapeutics Announces Resignation of Dr. Lewis T. "Rusty" Williams From Board of Directors Business Wire
Dec-20-19 01:54PM  Head of big South San Francisco biotech thriving in first CEO role American City Business Journals
Dec-16-19 06:17PM  Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents -5.80%
Dec-10-19 11:14AM  Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy ? Insider Monkey +5.14%
Nov-09-19 07:00AM  Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting Business Wire
Nov-08-19 01:02PM  Insiders Roundup: Crocs, OPKO Health GuruFocus.com
Nov-06-19 06:45PM  Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM  Five Prime Therapeutics Reports Third Quarter 2019 Results Business Wire
Oct-30-19 10:33AM  Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-24-19 04:01PM  Five Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call Business Wire
Oct-11-19 04:04PM  Insiders Roundup: Facebook, American Defense Systems GuruFocus.com
08:14AM  The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 09:57PM  South San Francisco biotech to cut another 70 jobs, may sublease space American City Business Journals
04:01PM  Five Prime Announces Restructuring Business Wire
Oct-02-19 07:30AM  Looking for 1,600% Returns? Biotech Has No Shortage of Analyst Optimism Bloomberg +5.15%
Sep-30-19 03:01AM  Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress Business Wire -9.36%
Sep-20-19 09:59AM  Peninsula biotech CEO resigns in latest corner office switch American City Business Journals
Sep-19-19 04:05PM  Five Prime Therapeutics Announces Management Transition Business Wire
12:18PM  What Kind Of Shareholder Owns Most Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock? Simply Wall St.
Aug-22-19 07:45PM  Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire
Aug-15-19 10:16PM  Edited Transcript of FPRX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 06:25PM  Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM  Five Prime Therapeutics Reports Second Quarter 2019 Results Business Wire
Aug-01-19 03:06PM  Cancer-fighting Peninsula company postpones $92 million IPO American City Business Journals
Jun-25-19 11:56AM  Estimating The Fair Value Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Simply Wall St.
Jun-24-19 04:05PM  Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors Business Wire
01:28PM  Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy? Insider Monkey
Jun-18-19 08:50AM  Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session Zacks
Jun-09-19 03:05PM  Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors Business Wire
03:00PM  Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire
Jun-01-19 09:01AM  Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting Business Wire
May-24-19 04:01PM  Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire
May-17-19 12:45PM  Edited Transcript of FPRX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-15-19 06:39PM  Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors Business Wire
05:45PM  Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting Business Wire
May-09-19 11:23AM  Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript Motley Fool -5.03%
May-08-19 06:45PM  Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:39PM  Five Prime Therapeutics: 1Q Earnings Snapshot Associated Press
04:05PM  Five Prime Therapeutics Reports First Quarter 2019 Results Business Wire
May-01-19 10:33AM  Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline Zacks
Apr-30-19 09:04AM  Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO? American City Business Journals -7.20%
Apr-17-19 07:56PM  Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8 Business Wire
01:27PM  What Should You Know About Five Prime Therapeutics, Inc.'s (NASDAQ:FPRX) Earnings Trajectory? Simply Wall St.
Mar-25-19 09:19AM  Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals
Mar-20-19 02:09PM  Edited Transcript of FPRX earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-19-19 09:28AM  Will Five Prime Therapeutics Continue to Surge Higher? Zacks
Mar-11-19 06:00AM  Five Prime Has 5 Drugs in its Pipeline MoneyShow
Mar-05-19 06:05PM  Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference Business Wire
Feb-26-19 09:47PM  Five Prime Therapeutics Inc (FPRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
Feb-20-19 08:05PM  Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150 Business Wire
Feb-07-19 04:05PM  Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26 Business Wire
Feb-04-19 05:05PM  Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum Business Wire
Jan-30-19 11:45PM  Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals
Jan-28-19 09:37AM  MacroGenics Up on Lifting of Partial Hold on Cancer Candidate Zacks -8.42%
Jan-24-19 03:13AM  Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue? Zacks
Jan-17-19 02:05PM  Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium Business Wire +5.98%
Jan-16-19 07:40AM  Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-15-19 05:08PM  Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line American City Business Journals +9.40%
04:05PM  Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities Business Wire
Jan-14-19 06:41PM  Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium Business Wire
Jan-13-19 03:50PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-12-18 04:05PM  Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Nov-29-18 04:05PM  Five Prime Therapeutics Announces Changes to its Board of Directors Business Wire
Nov-27-18 07:15AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Nov-20-18 04:05PM  Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference Business Wire
01:52PM  Edited Transcript of FPRX earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 04:05PM  Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein Business Wire
Nov-12-18 10:21AM  Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more American City Business Journals
Nov-09-18 08:40AM  New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-06-18 06:15PM  Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:09PM  Five Prime Therapeutics: 3Q Earnings Snapshot Associated Press
04:05PM  Five Prime Therapeutics Announces Third Quarter 2018 Financial Results Business Wire
Nov-05-18 10:36AM  Five Prime Therapeutics Announces David V. Smith Will Join as Chief Financial Officer Business Wire
Nov-01-18 10:23AM  Big pharma leases almost 500,000 square feet for new research center American City Business Journals +7.00%
Oct-23-18 04:05PM  Five Prime Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 6 Business Wire
Oct-16-18 09:00AM  Five Prime Therapeutics Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150 Business Wire +6.18%
Oct-10-18 02:42PM  Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-01-18 08:00AM  Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Business Wire
Sep-26-18 04:05PM  Five Prime Therapeutics to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
Sep-10-18 09:00AM  Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Business Wire
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerMay 14Buy4.10293,5871,203,7074,179,093May 18 08:02 PM
BVF PARTNERS L P/IL10% OwnerDec 20Buy4.05515,0202,085,8313,929,792Dec 26 05:59 PM
BVF PARTNERS L P/IL10% OwnerDec 09Buy4.02135,000542,3633,648,474Dec 11 06:13 PM
BERGER FRANKLIN MDirectorDec 03Sale4.0047,890191,5605,000Dec 04 06:28 PM
BERGER FRANKLIN MDirectorDec 02Sale3.9232,090125,79352,890Dec 04 06:28 PM
BVF PARTNERS L P/IL10% OwnerNov 22Buy3.401,120,0103,808,1463,534,600Nov 26 05:59 PM
BVF PARTNERS L P/IL10% OwnerNov 05Buy4.00968,1123,872,4482,958,503Nov 07 07:22 PM
BVF PARTNERS L P/IL10% OwnerOct 31Buy3.856,83326,3042,461,782Oct 31 06:24 PM
BVF PARTNERS L P/IL10% OwnerOct 30Buy3.8920,08178,1572,458,366Oct 31 06:24 PM
BVF PARTNERS L P/IL10% OwnerOct 29Buy3.902,4009,3532,447,977Oct 31 06:24 PM
BVF PARTNERS L P/IL10% OwnerOct 25Buy3.7530,782115,3492,446,950Oct 25 05:43 PM
BVF PARTNERS L P/IL10% OwnerOct 24Buy3.74135,388506,9872,431,222Oct 25 05:43 PM
BVF PARTNERS L P/IL10% OwnerOct 23Buy3.753,20011,9862,355,186Oct 25 05:43 PM
BVF PARTNERS L P/IL10% OwnerOct 08Buy3.6860,412222,4972,351,986Oct 08 05:40 PM
BVF PARTNERS L P/IL10% OwnerOct 07Buy3.75525,0701,968,6642,320,979Oct 08 05:40 PM
BVF PARTNERS L P/IL10% OwnerOct 04Buy3.7416,00059,8002,054,006Oct 08 05:40 PM
Knickerbocker Aron MarcPresident & CEOJun 07Option Exercise5.5411,35762,918195,828Jun 10 01:53 PM